IN2014DN08398A - - Google Patents

Info

Publication number
IN2014DN08398A
IN2014DN08398A IN8398DEN2014A IN2014DN08398A IN 2014DN08398 A IN2014DN08398 A IN 2014DN08398A IN 8398DEN2014 A IN8398DEN2014 A IN 8398DEN2014A IN 2014DN08398 A IN2014DN08398 A IN 2014DN08398A
Authority
IN
India
Prior art keywords
biomarker
parkinson
disease
drug
relates
Prior art date
Application number
Other languages
English (en)
Inventor
Dario Alessi
Muratul Muqit
Original Assignee
Univ Dundee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Dundee filed Critical Univ Dundee
Publication of IN2014DN08398A publication Critical patent/IN2014DN08398A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IN8398DEN2014 2012-04-11 2013-04-10 IN2014DN08398A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201206382A GB201206382D0 (en) 2012-04-11 2012-04-11 Parkinson's disease biomarker
PCT/GB2013/050926 WO2013153386A1 (fr) 2012-04-11 2013-04-10 Biomarqueur de la maladie de parkinson

Publications (1)

Publication Number Publication Date
IN2014DN08398A true IN2014DN08398A (fr) 2015-05-08

Family

ID=46177150

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8398DEN2014 IN2014DN08398A (fr) 2012-04-11 2013-04-10

Country Status (5)

Country Link
US (1) US20150104806A1 (fr)
EP (1) EP2836842A1 (fr)
GB (1) GB201206382D0 (fr)
IN (1) IN2014DN08398A (fr)
WO (1) WO2013153386A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3441769B1 (fr) * 2014-02-18 2022-06-22 Tokyo Metropolitan Institute of Medical Science Protéine ubiquitine phosphorylée
EP3288963B1 (fr) * 2015-05-01 2020-12-23 Wo, Andrew Man Chung Polypeptide à domaine c-terminal pink1 et leurs méthodes d'utilisation dans le traitement du cancer
GB201516342D0 (en) * 2015-09-15 2015-10-28 Univ Dundee Downstream targets of PINK1
WO2017053718A2 (fr) * 2015-09-23 2017-03-30 Boston Medical Center Corporation Biomarqueurs pour la détection précoce de la maladie de parkinson
WO2019028106A1 (fr) * 2017-08-01 2019-02-07 Cove Bio Llc Biomarqueurs associés à la maladie de parkinson
WO2020187104A1 (fr) * 2019-03-19 2020-09-24 中南大学湘雅医院 Procédé d'aide au diagnostic et au traitement de la maladie de parkinson, et réactif

Also Published As

Publication number Publication date
WO2013153386A1 (fr) 2013-10-17
EP2836842A1 (fr) 2015-02-18
GB201206382D0 (en) 2012-05-23
US20150104806A1 (en) 2015-04-16

Similar Documents

Publication Publication Date Title
WO2013066764A3 (fr) Marqueurs de signature de la maladie d'alzheimer et procédés d'utilisation
IN2014DN08398A (fr)
NZ735173A (en) Biomarkers for the diagnosis and/or prediction of susceptibility to mental and neurodegenerative disorders
EP3464638A4 (fr) Utilisation de biomarqueurs pour déterminer la sensibilité au traitement d'une maladie
MX2016002423A (es) Composiciones y metodos de diagnostico para el tratamiento de glioblastoma.
WO2015094995A3 (fr) Biomarqueurs de signature génique de réponse tumorale à des antagonistes de pd-1
EP3060913A4 (fr) Biomarqueurs et procédés de diagnostic pour la maladie d'alzheimer et d'autres troubles neurodégénératifs
WO2014140254A9 (fr) Interface utilisateur améliorée pour l'acquisition, l'affichage et l'analyse de données de diagnostic ophtalmologique
MX356802B (es) Marcadores biologicos para identificar pacientes para tratamiento con antagonistas de vegf.
IL246917A0 (en) Biomarker and early diagnosis methods for Alzheimer's disease
BR112013010015A2 (pt) aparelho e método para detecção não invasiva de doenças que afetam as propriedades estruturais em tecidos biológicos
BR112013022493A2 (pt) equipamento e método para examinar, diagnosticar ou auxiliar no diagnóstico e no tratamento de problemas funcionais de visão
MX358474B (es) Biomarcadores salivales específicos para detección de riesgo, diagnóstico temprano, pronóstico y vigilancia de las enfermedades de alzheimer y de parkinson.
WO2012173976A3 (fr) Procédés et appareil pour évaluer l'activité d'un organe et utilisations de ceux-ci
WO2015013508A3 (fr) Procédés permettant de diagnostiquer et de traiter une maladie du système immunitaire
EP2723866A4 (fr) Procédés de pronostic et/ou de diagnostic d'une maladie neurodégénérative, procédés d'identification de composés candidats et composés pour le traitement d'une maladie neurodégénérative
AP2015008366A0 (en) 2-Phenyl-5-heterocyclyl-tetrahydro-2H-pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders
BR112014014960A2 (pt) métodos para o diagnóstico da doença de alzheimer
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event
NZ729773A (en) Biomarkers for disease progression in melanoma
IN2014DN08537A (fr)
PH12017502099A1 (en) Methods for diagnosing and assessing treatment for cushing's syndrome
MX2017001293A (es) Metodos y composiciones para diagnosticar y tratar trastornos inflamatorios del intestino.
BR112015027249A2 (pt) método de diagnóstico de câncer
WO2014052685A3 (fr) Dispositifs et méthodes d'analyse monocellulaire